Pictrelisib

Drug Profile

Pictrelisib

Alternative Names: GDC-0941; Pictilisib; RG-7321

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PIramed; The Institute of Cancer Research
  • Developer Brighton & Sussex University Hospitals NHS Trust; Genentech; Roche
  • Class Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Apr 2016 Genentech completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, Israel, Italy, South Korea, Malaysia, Mexico, New Zealand, Peru, Russia, Singapore, Spain, Thailand and the UK (NCT01437566)
  • 01 Apr 2016 Genentech completes a phase II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) in USA, Australia, Spain, Russia, Israel, Hungary, Argentina, Netherlands, United Kingdom, Ukraine, Italy, Germany, France, Chile, Canada, Brazil (PO) (NCT01493843)
  • 01 Mar 2016 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top